Drug Database
CO

COVID-19 vaccine (Abdala / CIGB 66 / CIGB66)

✓ Approved

CIGB · Vaccine · Vaccine

What is COVID-19 vaccine?

COVID-19 vaccine is a vaccine developed by CIGB. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesAbdala, CIGB 66, CIGB66
CompanyCIGB
Drug ClassVaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, CIGB

Therapeutic Indications

COVID-19 vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsCOVID-19✓ Approved

Related Research Articles

PubMedJournal of thoracic disease2026-05-25

Incidence and risk factors of vaccination hesitancy among early-stage lung cancer patients: a cross-sectional study.

Zhang Fangyuan F, Liu Lifeng L, Zhao Jing J

Patients with lung cancer are highly prevalent and vulnerable to coronavirus disease 2019 (COVID-19), and vaccination is believed to be the most effective weapon to control this epidemic. Besides, COVID-19 vaccination is always withheld among patients with advanced lung cancer receiving therapy. Thus, this study aims to explore the prevalence of COVID-19 vaccination hesitancy and identify its associated factors in patients with early-stage lung cancer. A cross-sectional study of 728 patients with early-stage lung cancer before surgery was conducted to assess their level of knowledge, attitudes and hesitancy toward COVID-19 vaccination at Tianjin Medical University Cancer Hospital and Institute, from May to November 2023 in China. Multivariate logistic regression analysis was used to identify the factors influencing the likelihood of receiving a COVID-19 vaccination among early-stage lung cancer patients. A total of 151 (20.7%) preoperative lung cancer patients with early stage reported concerns about the acceptance of COVID-19 vaccines. Multivariate logistic regression analysis revealed that admitted patients with early-stage lung cancer before surgery who thought the vaccine was not safe (vs. yes) [odds ratio (OR) =5.305, 95% confidence interval (CI): 1.964-14.327; P=0.001], who would not recommend their family members or friends to get vaccinated (vs. yes) (OR =2.511, 95% CI: 1.287-4.901; P=0.007), and who would not like to pay for the vaccine (vs. yes) (OR =3.841, 95% CI: 2.091-7.054; P<0.001) were more likely to refuse to get vaccinated. Conversely, participants who had no concerns about the vaccine exacerbating their cancer prognosis (vs. yes) (OR =0.203, 95% CI: 0.071-0.577; P=0.003) were more likely to be open to vaccination. In addition, the top two concerns related to COVID-19 vaccine acceptance were immediate serious adverse effects (48.3%) and long-term adverse effects after COVID-19 vaccination (87.4%). This study provides preliminary estimates of the rate of COVID-19 vaccination hesitancy among preoperative patients with early-stage lung cancer. The safety of COVID-19 vaccines remains a key determinant of vaccination acceptance. Research on the safety and efficacy of COVID-19 vaccines among patients with lung cancer is urgently needed to promote a global vaccination campaign.

PMID 42182665
Read full article →
PubMedColombia medica (Cali, Colombia)2026-05-25

Factors influencing COVID-19 vaccination acceptance when knowing potential side effects: a study in Colombia.

Álvarez-Najar Juan Pablo JP, Iguacel Isabel I, Martínez-Jarreta Begoña B, Couto-Alfonso Sergio S et al.

To examine the determinants of COVID-19 vaccine acceptance in Colombia, with particular emphasis on individuals' responses to possible side effects. A cross-sectional study was conducted using an anonymous online questionnaire in Colombia between January and March 2023. The ad hoc survey collected sociodemographic data, COVID-19 history, vaccination status, and adverse effects. Descriptive analyses, chi-square tests, and multinomial logistic regression (aOR, 95% CI) were performed (p <0.05). The 40.2% of respondents expressed doubts or would have rejected vaccination had they known about possible side effects beforehand. Women were more likely to hold doubts or reject the vaccine after experiencing adverse effects. Participants who experienced side effects were more likely to question their decision to vaccinate. Younger individuals were less likely than older adults to develop negative attitudes after experiencing side effects. Those who had received only one dose were more likely to doubt or reject further vaccination, whereas individuals with multiple doses were less likely to do so. Participants with asymptomatic COVID-19 were less likely to refuse vaccination after learning about potential side effects, possibly because they trusted their immune system more or had a stronger desire to protect others. Vaccination hesitancy was associated with female sex, prior adverse effects, and fewer doses, whereas younger age was associated with greater acceptance. These findings highlight the need for targeted risk communication to address safety concerns and strengthen vaccine confidence.

PMID 42183073
Read full article →
PubMedPublic health in practice (Oxford, England)2026-05-25

Inadvertent post-expiry COVID-19 vaccination in 282 seniors: Safety, efficacy, and implications for extended off-label stability data.

Klasson Henrik H

To describe safety and clinical outcomes after inadvertent post-expiry administration of Pfizer-BioNTech SARS-CoV-2 vaccine to adults aged ≥80 years in Swedish primary care; indicate what can (and cannot) be inferred about efficacy from real-world follow-up; and identify system needs for clearer expiry labelling and producer-led, longer-horizon post-expiry evidence. The study was not designed to estimate vaccine effectiveness. Service evaluation; observational single-arm cohort (ambispective). After discovery that 282 recipients had received doses 3-5 months past the labelled expiry, 280 survivors were informed and offered in-date revaccination within ∼4 weeks. Clinicians recorded revaccination uptake, adverse events exceeding expected post-mRNA symptoms after expired and (if applicable) in-date doses, and any confirmed/strongly suspected COVID-19 prior to revaccination; deaths were attributed via records. A change in manufacturer presentation of shortened/altered expiry encountered locally at point of care was documented. 208/280 accepted revaccination; 72/280 declined. Two deaths occurred from age-related/pre-existing illness (not vaccination-related). No serious or unexpected adverse events were recorded after expired or in-date doses. A small number reported mild, self-limited illness compatible with COVID-19; there were no hospitalisations and no laboratory-confirmed cases. In this cohort of older seniors, inadvertent post-expiry vaccination was followed by no safety signal and no COVID-19 hospitalisations; effectiveness cannot be quantified from this design. Given recurring human error and cold-chain stress, clearer expiry labelling and transparent, real-life post-expiry stability/efficacy data (weeks-months; including temperature-excursion profiles) are needed to support patient safety, reduce wastage, and strengthen preparedness.

PMID 42182578
Read full article →
PubMedInternational journal of public health2026-05-25

Influence of the Workplace on Influenza and COVID-19 Vaccination Acceptance Among Swiss Healthcare Workers During Season 2021/22.

Morgel Olga O, Czock Astrid A, Fehr Jan J, Lang Phung P

Healthcare workers (HCWs) are essential in preventing and controlling infectious diseases and can influence public trust in vaccines. This study compares vaccination behaviors among HCWs in a Swiss hospital setting with those in primary care and identifies key factors influencing vaccine acceptance. An online questionnaire was distributed to HCWs at a cantonal hospital in Central Switzerland. The results were compared with a previous nationwide survey of German-speaking HCWs in primary care using descriptive statistics, chi-square tests, and multivariable logistic regression analyses. Influenza vaccination coverage was 37.2% in hospitals and 59.8% in primary care. COVID-19 vaccination rates were high in both settings (89.1% and 92.7%, respectively). Physicians and older HCWs were significantly more likely to be vaccinated than nurses and younger staff. Vaccination training and prior vaccination history were associated with higher vaccination rates and stronger recommendation behavior. The most common reasons supporting vaccination were self-protection and patient protection. Vaccination behavior among HCWs differs considerably by healthcare setting and profession. Targeted vaccination training, particularly for younger HCWs and nurses in hospital settings, may help increase vaccine acceptance.

PMID 42181983
Read full article →
PubMedThe Annals of thoracic surgery2026-05-25

Pediatric Heart Transplant Outcomes Using COVID-19-Positive Donors in the United States.

Bilgili Ahmet A, Kugler Liam R LR, Wong Leanne A LA, Shillingford Michael S MS et al.

Little is known about the impact of prior COVID-19 infection in an organ donor on the viability of pediatric donor hearts. In a national cohort, we assess if COVID-19+ donor status impacts outcomes after cardiac transplantation. We performed a retrospective review of the United Network for Organ Sharing databases for all pediatric heart transplants since the inception of COVID-19 data collection (April 2020-December 2024). A COVID-19+ donor was defined as "ever having a positive upper or lower respiratory SARS-CoV-2 nucleic acid amplification or antigen test within 21 days of Recovery". We utilized a nearest neighbor 1:1 propensity score match to adjust for differences between recipients of COVID-19+ and non-COVID-19+ donor hearts. Among 2,245 pediatric heart transplants, 100/2,245=4.5% utilized COVID-19+ donor hearts. These recipients had lower BMI(16.8 versus 17.8 kg/m2,p=0.02), but were otherwise similar in age (6 versus 8 years,p=0.09) and congenital heart disease prevalence (53% versus 51.5%,p=0.85). In matched analyses (COVID-19+ versus non-COVID-19+), rates of postoperative stroke (1% versus 5%,p=0.22), dialysis (8% versus 6%,p=0.78), and acute rejection (9% versus 14%,p=0.39) did not differ between groups. COVID-19 was not reported as a cause of death in any patients who died with a transplanted COVID-19+ heart. One-year post-transplant survival was 91.9%(95%CI=86.2-97.9%) for COVID-19+ donors versus 93.2%(95%CI-88.1-98.6%) for non-COVID-19+ donors (log-rank p=0.71). COVID-19+ donor status was not associated with increased one-year mortality(OR=0.88,95%CI=0.36-1.85;p=0.76). Pediatric heart transplants from COVID-19+ donors demonstrated comparable outcomes to non-COVID-19+ donors. These findings support the safe use of COVID-19+ donor hearts, though longer follow-up is needed.

PMID 42178087
Read full article →
PubMedCureus2026-05-25

Provincial Trends in Childhood Vaccine Coverage in Afghanistan From 2000 to 2024: An Ecological Study of Findings From the Institute for Health Metrics and Evaluation.

Khan Ahmad A, Tidman Melanie M

This study analyzes vaccination coverage trends across 34 provinces in Afghanistan from 2000 to 2024, using data from the Institute for Health Metrics and Evaluation (IHME). Coverage rates for bacillus Calmette-Guérin (BCG), diphtheria-tetanus-pertussis third dose (DTP3), measles-containing vaccine first dose (MCV1), polio vaccine (three doses), pneumococcal conjugate vaccine third dose (PCV3), hepatitis B vaccine third dose (HepB3), Haemophilus influenzae type b vaccine third dose (Hib3), and rotavirus vaccine (RotaC) were assessed using the Kruskal-Wallis and Friedman tests. The Friedman test and Kruskal-Wallis H test were used to assess significant differences in vaccination coverage trends across the 34 provinces in Afghanistan from 2000 to 2024, enabling a comprehensive analysis of provincial and temporal trends. A downward trend in vaccination coverage was observed during the COVID-19 pandemic and after international aid limitations following the political change that occurred in Afghanistan in 2021. This decline in coverage may be associated with disruptions in vaccine distribution during these critical periods. Besides individual factors, vaccination adherence is influenced by health system factors, including vaccine availability and accessibility. The results of the Kruskal-Wallis and Friedman tests showed significant variability in vaccination coverage trends across the 34 provinces from 2000 to 2024. These findings highlight the need for intensive efforts to improve vaccination coverage in all 34 provinces to protect those most at risk.

PMID 42182556
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about COVID-19 vaccine